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Abstract
Background Cystic fibrosis per se can sometimes lead to
hyponatremia, hypokalemia, hypochloremia or hyperbicar-
bonatemia. This tendency was first documented 60 years ago
and has subsequently been confirmed in single case reports or
small case series, most of which were retrospective. However,
this issue has not been addressed analytically.We have therefore
systematically reviewed and analyzed the available literature on
this subject.
Methods This was a systematic review of the literature.
Results The reports included in this review cover 172 sub-
acute and 90 chronic cases of electrolyte imbalances in pa-
tients with cystic fibrosis. The male:female ratio was 1.57.
Electrolyte abnormalities were mostly associated with clini-
cally inapparent fluid volume depletion, mainly affected
patients aged ≤2.5 years, frequently tended to recur and often
were found before the diagnosis of cystic fibrosis was
established. Subacute presentation often included an history
of heat exposure, vomiting, excessive sweating and pulmo-
nary infection. History of chronic presentation, in contrast,
was often inconspicuous. The tendency to hypochloremia,
hypokalemia and metabolic alkalosis was similar between
subacute and chronic patients, with hyponatremia being more
pronounced (P <0.02) in subacute compared to chronic pre-
sentations. Subacute cases were treated parenterally; chronic
ones were usually managed with oral salt supplementation.
Retention of urea and creatinine was documented in 38 % of
subacute cases.
Conclusions The findings of our review suggest that physi-
cians should be aware that electrolyte abnormalities can occur
both as a presenting and a recurring feature of cystic fibrosis.
Keywords Cystic fibrosis . Hypokalemia . Hyponatremia .
Metabolic alkalosis
Introduction
Hyponatremia, hypokalemia, hypochloremia or hyperbicar-
bonatemia are conditions that can be found in cystic fibrosis
patients on drug treatment [1, 2]. Hyponatremia and hypokale-
mia can also be found in cystic fibrosis patients with diabetes
mellitus, a major comorbidity of this disease. However, these
electrolyte abnormalities are sometimes a consequence of the
disease itself [3]. This tendency, first documented following
heat exposure approximately 60 years ago [4], has subsequent-
ly been confirmed in several single case reports or small case
series, most of which were retrospective. However, the subject
has not been addressed analytically [3]. We therefore system-
atically reviewed and analyzed all available literature. Our aims
were to describe in detail electrolyte abnormalities, suggest
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preventive and therapeutic tools and warn physicians about the
possible occurrence of electrolyte abnormalities as a presenting
feature and complication of cystic fibrosis.
Methods
Between October 2012 and August 2013 we conducted a
thorough computer-based search for the terms “cystic fibrosis
alkalosis,” ”cystic fibrosis electrolyte abnormalities,” “cystic
fibrosis Bartter’s,” “cystic fibrosis dehydration,” “cystic fibrosis
heat exhaustion,” “cystic fibrosis hypoelectrolytemia,” “cystic
fibrosis hypokalemia,”, “cystic fibrosis hyponatremia,” “cystic
fibrosis inappropriate antidiuretic hormone,” “cystic fibrosis
pseudo-Bartter‘s,” “cystic fibrosis salt depletion” and “cystic
fibrosis SIADH” in the U.S. National Library of Medicine
database and in the Web-based Google research engine. For
this purpose we used the principles established by the UK
Economic and Social Research Council guidance on the con-
duct of narrative synthesis and on the Preferred Reporting Items
for Systematic Reviews and Meta-Analyses statement [5]. For
the final analysis we exclusively selected reports available as a
full-length article or as a letter, all of which included individu-
ally described cases of hyponatremia (≤134 mmol/L),
hypochloremia (≤100 mmol/L), hypokalemia (≤3.4 mmol/L)
or alkalosis (bicarbonatemia ≥27 mmol/L) in cystic fibrosis
patients with or without a pathological increase in blood urea
and creatinine values. Characteristic gastrointestinal or pulmo-
nary findings and a persistently elevated sweat chloride con-
centration (≥60 mmol/L) were the prerequisites for di-
agnosis [3]. Studies addressing the mechanisms under-
lying the tendency towards the above-mentioned electro-
lyte abnormalities were also sought. Reports published in
languages other than English, French, German, Italian,
Portuguese or Spanish were excluded. If the same case was
present in different publications, we considered the most com-
plete description.
Reports of cystic fibrosis patients with electrolyte abnor-
malities possibly caused by drugs (especially thiazide or loop
diuretics and alkalinizing agents such as calcium carbonate or
sodium bicarbonate), by cystic fibrosis-related diabetes
mellitus or by acute diarrhea were excluded. Patients with a
medical history consistent with posthypercapnic alkalosis
were also excluded [6]. The presentation was considered
subacute when linked to circumstances such as hot weather,
vomiting or a respiratory disease and lasted ≤14 days [7, 8].
On the contrary, the presentation was considered chronic in
patients without symptoms or with symptoms that persisted
>14 days [7, 8]. The following data for each case were
collected: age, gender, laboratory test results, heat exposure,
clinical presentation, chest infection, tendency of the electro-
lyte abnormalities to recur and previous diagnosis of cystic
fibrosis. The genotype was not specifically addressed since in
cystic fibrosis the association between the physical trait and
the underlying genotype is not strong [9].
Numerical data were presented either as the median and
interquartile range or as a “box and whiskers plot”, categorical
data were presented as relative frequency. The two-sided
Wilcoxon–Mann–Whitney test and the Fisher exact test were
performed for analysis. Significance was assumed when P
was<0.05.
Research results
The flowchart of the literature research process (Fig. 1) indi-
cates that the initial research resulted in the identification of
408 publications of which 228 remained after duplicates (i.e.
publications found with two or more research terms) were
excluded. Of these 228 publications, 168 were reviewed in
detail and 70 were retained for the final analysis. Thirty-one
reports relevant to the subject were found in the references of
these latter 70 reports. Hence, a total of 101 reports published
between 1951 and 2013 were included in the final analysis [4,
7, 8, 10–107]: 88 in English [4, 7, 8, 10–94], six in Spanish
[95–100], three in German [101–103], two in French [104,
105] and two in Portuguese [106, 107]. They had been report-
ed from the following countries: Arab Emirates (N =1),
Argentina (N =1), Australia (N =4), Austria (N =1), Belgium
(N =2), Brazil (N =2), Canada (N =6), Chile (N =3), China
(N =1), Cuba (N =1), Egypt (N =1), France (N =5), Germany
(N =3), Great Britain (N =9), Greece (N =2), India (N =1),
Iran (N =1), Italy (N =3), Jordan (N =1), Kuwait (N =1),
Lebanon (N =1), Nepal (N =1), Panama (N =1), Puerto Rico
(N =1), Peru (N =1), Saudi Arabia (N =1), Serbia (N =2),
Spain (N =5), Sweden (N =1), Switzerland (N =5), Thailand
(N =2), Turkey (N =7), United States of America (N =24).
Records identified through search in in the U.S. National Library of 
Medicine database (N = 408)
Records searched after duplicates removed (N = 228)
Records excluded after abstract and title review (N = 60)
Citations assessed in detail for eligibility (N = 168)
Article excluded (N = 98)
not pertaining (N = 94)
language (N = 3)
duplicate cases of other reports (N = 1)
Eligible reports (N = 101)
Reports found in reference lists (N = 31)
Fig. 1 Flowchart of the literature research process. Of the 101 reports
included in the final analysis, 11 were identified exclusively from the
Web-based Google research engine
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Results
Presentation
In the 262 cystic fibrosis patients (male:female ratio1.57; P <
0.01) described in the 101 reports reviewed, hypochloremia
(noted in 219/223 patients with this measurement),
hyponatremia (in 206/218 patients), hyperbicarbonatemia (in
188/205 patients) or hypokalemia (in 161/199 patients) were
found. Most cases of these electrolyte imbalances were in
combination with some other condition, but less frequently they
occurred in isolation (an electrolyte abnormality was detected in
isolation when the other electrolytes went unmeasured), as
shown in Table 1. Three-quarters of the patients were ≤2.5 years
of age when diagnosed with electrolyte abnormalities, and
approximately 60%were diagnosed with electrolyte abnormal-
ities before cystic fibrosis was identified (in at least 36 of these
patients, a pediatric kidney disease specialist was involved
because the initial diagnosis of Bartter syndrome was
suspected). Circulating renin and aldosterone levels (Table 1),
assessed only in a minority of cases, were almost always
elevated (90 % and 86 %, respectively).
Clinical presentation was subacute in 172 cystic fibrosis
patients (66 %) and chronic in the remaining 90 (34 %).
Hyponatremia was significantly (P <0.02) more pronounced
in patients with subacute rather than with chronic presentation
(Table 1; Fig. 2). Renal function studies were performed only
in a minority of subacute cases (N =69), with retention of urea
and creatinine documented in 26 patients (38 %).
In patients with either subacute or chronic presentation,
these electrolyte abnormalities were associated with respira-
tory infections, excessive sweating, increased body tempera-
ture, failure to thrive, vomiting, heat exposure and fluid vol-
ume depletion, but they were significantly more frequent in
patients with subacute presentation (Table 2). Tendency to
recur was found in both subacute and chronic presentations,
but was significantly (P <0.02) more common in subacute
cases. Respiratory disease was significantly more pronounced
in patients with electrolyte abnormalities than in those without
these abnormalities in both subacute and in chronic cases
[70, 94]. All reported patients had normal or low blood
Table 1 Laboratory values in cystic fibrosis patients with a tendency to hyponatremia (≤134 mmol/L), hypokalemia (≤3.4 mmol/L), hypochloremia
(≤100 mmol/L) or hyperbicarbonatemia (≥27 mmol/L)
Demographic and clinical data All Subacute presentation Chronic presentation Significance (subacute vs. chronic)
N Value N Value N Value
Gender, males/females (N) 262 160/102b 172 109/63b 90 51/39b NS
Age (years) 262 0.58 [0.33-2.5] 172 0.50 [0.33-2.5] 90 0.58 [0.40-2.4] NS
Cystic fibrosis undiagnosed (N) 262 152 172 112 90 40 P<0.005
Kidney injury (N) 69 26 69 26 – – –
Circulating
Sodium (mmol/L) 218 125 [120–129] 156 124 [119–129] 62 127 [122–131] P<0.02
Potassium (mmol/L) 199 2.8 [2.3-3.4] 138 2.8 [2.4-3.4] 61 2.6 [2.1-3.2] NS
Chloride (mmol/L) 223 71 [62–81] 146 71 [63–82] 77 70 [60–81] NS
Bicarbonate (mmol/L) 205 37 [32–42] 123 38 [33–42] 82 36 [31–41] NS
Renina, elevated 31 28 18 16 13 12 NS
Aldosterone, elevated 29 25 16 14 13 11 NS
NS, Not significant
Numerical data are presented as the median and interquartile range (IQR) in square brackets; categorical data as are presented as relative frequency,
unless otherwise indicated
a Estimated by either assays of plasma renin activity or by direct renin assay
bP<0.01 (male vs. female)
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Fig. 2 Blood levels of sodium, chloride, potassium and bicarbonate in
cystic fibrosis patients with electrolyte abnormalities. The results are
given as “box and whiskers plot”: bottom and top of box 25th and 75th
centile, respectively, middle of box 50th centile (the median), ends of
whiskers 3rd and 97th centile, respectively
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pressure, except for an adolescent with a tendency to arterial
hypertension [80]. Sodium, potassium and chloride urinary
excretion were found to be reduced when measured before
treatment for fluid and electrolyte repair was initiated.
An adolescent with cystic fibrosis who took part in a
football practice on a summer morning developed rhabdomy-
olysis and was found to be dehydrated and hyponatremic [49].
Metabolic alkalosis may lead to compensatory hypoven-
tilation and C02 retention. To address this, an Australian group
evaluated the acid–base balance in cystic fibrosis patients with
chronic hypercapnia or exacerbations of respiratory disease and
in adult patients with hypercapnia due to an exacerbation of
their chronic obstructive pulmonary disease. The results of that
study showed that metabolic alkalosis contributes to hypercap-
nic respiratory failure in cystic fibrosis patients during exacer-
bation of the disease itself [44].
Prevalence of electrolyte abnormalities at diagnosis of cystic
fibrosis
Our literature research revealed only four reports addressing the
prevalence of electrolyte abnormalities when cystic fibrosis
was diagnosed. Hyponatremia was observed at diagnosis in
19 of 20 (95 %) Brazilian patients [42], whereas hypokalemia,
hyponatremia and hyperbicarbonatemia were found in ten of
110 (9 %) Jordanian patients [94], four of 13 (31 %) Peruvian
patients [95] and five of 120 (4 %) Indian patients [48].
Causes and clinical signs of fluid volume depletion in cystic
fibrosis
A few of the identified studies investigated the mechanisms
responsible for extracellular fluid volume depletion and elec-
trolyte abnormalities in cystic fibrosis [16, 21, 55, 57, 81]. The
results were as follows:
1) These patients underestimated their fluid needs and expe-
rienced excessive dehydration during extended exposure to
hot climates and during intense physical activity [16, 55].
2) In cystic fibrosis, sweat production, occurring under con-
ditions such as heat exposure or sport performances, was
associated with an increase in sodium concentration in the
sweat by approximately 30 mmol/L [21].
3) In salt-depleted patients with cystic fibrosis, clinical signs
of extracellular fluid depletion, such as pallor, prolonged
capillary refill, abnormal skin turgor, absent tears, dry
mucous membranes, sunken eyes and tachycardia, were
clinically less evident than in control subjects [57].
4) Apparently well hydrated and clinically stable cystic fi-
brosis patients had a low urinary sodium excretion [81]
with elevated levels of both circulating renin and aldoste-
rone [57], thus suggesting the presence of a chronic
condition of fluid volume depletion.
Syndrome of inappropriate antidiuresis
Three patients with advanced cystic fibrosis (2 men and 1
woman, aged 23, 25 and 28 years, respectively) and a pulmo-
nary exacerbation presented with hyponatremia (lowest value
from 114 to 123 mmol/L) and no clinical signs of extracellular
fluid volume depletion. Their acid–base balance and potassi-
um level were normal, blood urea level was rather low and
sodium and chloride urinary excretion were rather high.
Hence, the diagnosis of syndrome of inappropriate
antidiuresis was entertained [25, 77, 84].
Prevention and management of dyselectrolytemia
The salt content of a normal diet and of both breast milk and
infant formula may well be inadequate to meet general nutri-
tional requirements of cystic fibrosis patients [24, 26]. It has
therefore been recommended that infants with cystic fibrosis
who are fed breast milk or milk formula should normally be
provided a sodium chloride supplement of 3 mmol/kg body
weight. This dosage should be increased to 5–6 mmol/kg of
body weight under circumstances such as hot weather, arid
climate, excessive house heating or sports activity [24, 26,
Table 2 Factors associated with
hyponatremia, hypokalemia,
hypochloremia or
hyperbicarbonatemia in patients
with cystic fibrosis
Data are presented as the number
(N) of patients
Factors associated
with electrolyte
imbalance
All patients
(N =262)
Patients with
subacute presentation
(N =172)
Patients with
chronic presentation
(N =90)
Significance
(subacute vs.
chronic)
Dehydration 146 133 13 P<0.0001
Heat exposure 127 105 22 P<0.0001
Vomiting 94 79 15 P<0.0001
Failure to thrive 88 48 40 P<0.002
Increased body temperature 75 61 14 P<0.0001
Excessive sweating 48 45 3 P<0.0001
Chest infection 40 35 5 P<0.001
Tendency to recur 71 57 14 P<0.02
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54]. Nonetheless, the authors of one study reported that an
infant with cystic fibrosis developed severe hypernatremia
(177 mmol/L) as a result of a misunderstood excessive daily
supplement with one heaped teaspoon of table salt throughout
a 3-week period [22].
Subacute dehydration and electrolyte abnormalities were
repaired through the parenteral route in all reported cases,
except for three rather mild cases that were managed by
administration of oral rehydration solutions [17, 91, 93].
Discussion
This analysis shows that electrolyte abnormalities in cystic
fibrosis patients are almost always associated with fluid
volume depletion and are often clinically inapparent.
Metabolic alkalosis and hypokalemia mainly result from
renal tubular bicarbonate reabsorption, hydrogen secretion
and potassium excretion, all of which are crucially regulat-
ed by a chloride–bicarbonate exchanger located on the
intercalated cells and maintained in the presence of a
reduced renal function [108]. This laboratory constellation
is currently termed chloride depletion hypokalemic alkalosis
instead of volume contraction hypokalemic alkalosis [108],
taking into account that chloride depletion is the most
significant factor responsible for these electrolyte abnormal-
ities (Fig. 3).
These electrolyte abnormalities mainly affect cystic fibrosis
patients aged ≤2.5 years, involve males more frequently than
females, tend to recur and are often recognized before cystic
fibrosis is diagnosed. Patients with subacute presentation of
electrolyte abnormalities and dehydration often have a recent
history of heat exposure, vomiting, excessive sweating, in-
creased body temperature and respiratory infection. By contrast,
the medical history of patients with chronic presentation is
inconspicuous and subtle.
Medical history, low sodium, potassium and chloride uri-
nary excretion, frequent activation of the renin–aldosterone
system and occasional occurrence of some transient kidney
injury in patients with subacute presentation all support the
association between electrolyte abnormalities and fluid vol-
ume depletion in cystic fibrosis patients [109]. These patients
underestimate their fluid needs and experience dehydration
during exposure to heat conditions and physical activity at a
time when they have an enhanced sweat production.
Furthermore, a persisting and subtle condition of fluid volume
depletion is often present in clinically stable and apparently
well-hydrated cystic fibrosis patients.
Our review of the literature revealed a few adults with
advanced cystic fibrosis who experienced an isolated
hyponatremia event without fluid volume depletion and who
were diagnosed with a syndrome of inappropriate antidiuresis
[109]. However, we did not identify any case of hyponatremia
due to inappropriate antidiuresis in children, adolescents or
adults without advanced lung disease.
There are four possible consequences of electrolyte abnor-
malities in cystic fibrosis. These are:
1) Persistent sodium chloride depletion may cause failure to
thrive [110]: even though in this condition poor growth is
mainly linked to both pancreatic and lung disease, we
posit that failure to thrive might at times also be related to
chronic electrolyte abnormalities.
2) The lung disease of cystic fibrosis primarily develops
because thick mucus plugs predispose to respiratory in-
fections [9]. With electrolyte abnormalities and fluid vol-
ume depletion present, it is tempting to speculate that in
cystic fibrosis electrolyte abnormalities might further
Excessive*
Sweat Production
Gastrointestinal
Fluid Losses
Salt and 
Fluid Intake
Salt and Fluid 
Absorption
Extracellular fluid 
volume Depletion
Chloride
Depletion
Fever Heat ExposurePhysical ActivityDiarrhea
* with an abnormally 
high salt content
Renin-
Aldosterone 
System
Release of ADH Renal HCO3-
Regeneration
K+ shift from
extra- to intra-
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HCO3-K+Na+
VomitingFig. 3 Mechanisms underlying
the development of electrolyte
abnormalities in cystic fibrosis.
The crucial role of a reduced renal
function is not addressed in the
figure. ADH Antidiuretic
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worsen the density and the viscosity of the mucus
secretions.
3) In subjects with hyperbicarbonatemia, C02 retention de-
velops in order to restore blood hydrogen ion concentra-
tion towards normal. Hence, in some cystic fibrosis pa-
tients, C02 retention might be linked not only to the lung
disease but also to the hyperbicarbonatemia.
4) Adults with cystic fibrosis possess various potential risk
factors for the development of chronic kidney disease,
including cystic fibrosis-related diabetes mellitus, nephro-
toxic drug exposure, secondary amyloidosis and absorptive
hyperoxaluria. We speculate that in this hereditary disease
recurrent but often clinically inapparent fluid volume de-
pletion might be a further risk factor for chronic kidney
disease.
In patients with subacute presentation, fluid volume deple-
tion and electrolyte abnormalities require parenteral fluid and
electrolyte replacement with solutions rich in sodium, potassi-
um and chloride. Similar to the treatment for hypertrophic
pyloric stenosis, many institutions give dehydrated cystic fibro-
sis patients with electrolyte abnormalities a 5 % glucose solu-
tion that contains sodium chloride at approximately 80 mmol/L
and potassium chloride at 15–25 mmol/L [111]. Unfortunately,
assessment of the fluid volume state of these patients based on
physical examination and history is inaccurate. Yet, in cases
with metabolic alkalosis, the severity of alkalosis may help
clinicians estimate the fluid volume status and, therefore, the
amount of fluid required for repair: 10 ml/kg of body weight of
the above-mentioned solution reduces circulating bicarbonate
by approximately 3 mmol/L [111]. Rather severe hyponatremic
(<120 mmol/L) parenteral repair consists of a normal saline
solution [108]. Most patients with chronic presentation require
daily oral salt supplementation with 3 mmol/kg body weight.
This dosage should be increased to 5–6 mmol/kg under partic-
ular circumstances such as hot weather, arid climate, excessive
house heating or sport activities. When cystic fibrosis patients
present with a severe form of chronic electrolyte abnormalities
and dehydration, a period of extra-enteral (or parenteral) fluid
and salt supplementation could be necessary.
A significant limitation of this review is that the analysis
almost exclusively incorporated information from single case
reports or small retrospective case series of cystic fibrosis
patients. No attempt was made to objectively measure the
body water compartments of the patients. Finally, therapeutic
and preventive recommendations do not arise from scientific
analysis or clinical outcomes, but from authors’ opinions.
Conclusion
Cystic fibrosis itself tends to electrolyte abnormalities,
such as hypochloremia, hyponatremia, hypokalemia or
hyperbicarbonatemia, that are almost always associated with
an often clinically inapparent fluid volume depletion. In such
cases, kidney disease specialists are sometimes involved be-
cause the diagnosis of Bartter syndrome is initially suspected
by general pediatric practitioners (the fractional chloride ex-
cretion, which is >1.5 10−2 in Bartter syndrome and <0.5 10−2
in cystic fibrosis and other conditions with strong renal salt
retention, is a crucial diagnostic clue). While subacute presen-
tation is treated parenterally, chronic presentation is managed
with daily oral salt supplementation.
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